MedTrace Logo

Famotidine in Covid-19 Intensive Care Unit

NCT05122208 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-04-19

No results posted yet for this study

Summary

The COVID-19 disease, caused by SARS-CoV-2 virus, started in December 2019 and created a pandemic with high mortality and morbidity. Since a fully proven treatment has not been developed, the efficacy of currently available treatments is being investigated. Famotidine, an H2Receptor blocker, is one of the drug treatments being investigated. In this study, we aimed to investigate the effect of Famotidine treatment on the clinic and mortality of Covid-19 patients treated in the intensive care unit.

Conditions

  • COVID-19 Pandemic

Interventions

DRUG

Famotidine Tablets

160 mg/day Famotidine

Sponsors & Collaborators

  • Istanbul Medeniyet University

    lead OTHER

Principal Investigators

  • mesure Gul Nihan Ozden, MD · Istanbul Medeniyet University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-20
Primary Completion
2021-03-30
Completion
2021-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122208 on ClinicalTrials.gov